Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-07

Clinical Trial Update: Low Dose Tamoxifen for Mammographic Density Reduction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose tamoxifen to reduce mammographic density as a surrogate for breast cancer risk reduction; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tamoxifen (tamoxifen)

Snippet

Sponsor: Per Hall | Conditions: Risk Reduction, Mammographic Density Reduction | Phase 2 | Status: COMPLETED | Results posted: 2025-03-07